[{"id":"53a3393c-70b7-4bcc-a8e3-5120097c6768","acronym":"OVELIA","url":"https://clinicaltrials.gov/study/NCT04906395","created_at":"2021-05-28T13:52:36.773Z","updated_at":"2025-02-25T12:28:09.357Z","phase":"Phase 3","brief_title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","source_id_and_acronym":"NCT04906395 - OVELIA","lead_sponsor":"Tolmar Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-24"},{"id":"fe52e481-e906-4f7f-a53f-550a7128a15c","acronym":"EVANGELINE","url":"https://clinicaltrials.gov/study/NCT05607004","created_at":"2022-11-07T13:56:21.386Z","updated_at":"2025-02-25T12:38:26.751Z","phase":"Phase 2","brief_title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","source_id_and_acronym":"NCT05607004 - EVANGELINE","lead_sponsor":"Atossa Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 02/14/2023","start_date":" 02/14/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-24"},{"id":"fa762180-1ac0-4c2f-bfff-1035ccc3f515","acronym":"","url":"https://clinicaltrials.gov/study/NCT05669664","created_at":"2023-12-04T19:35:23.503Z","updated_at":"2025-02-25T15:20:12.831Z","phase":"Phase 2","brief_title":"Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers","source_id_and_acronym":"NCT05669664","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 04/11/2027","primary_completion_date":" 04/11/2027","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2025-02-12"},{"id":"a8e4ef32-1344-482b-a5f5-187c3f5e9c87","acronym":"YATAGARASU","url":"https://clinicaltrials.gov/study/NCT04325828","created_at":"2021-01-18T20:57:18.226Z","updated_at":"2025-02-25T15:26:19.647Z","phase":"Phase 2","brief_title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT04325828 - YATAGARASU","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 06/09/2021","primary_completion_date":" 06/09/2021","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"ac946163-6425-4f9a-8c1e-f35619d318be","acronym":"ROSE","url":"https://clinicaltrials.gov/study/NCT05377684","created_at":"2022-05-17T11:53:45.438Z","updated_at":"2025-02-25T17:25:34.281Z","phase":"","brief_title":"Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment","source_id_and_acronym":"NCT05377684 - ROSE","lead_sponsor":"Ipsen","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-01-31"},{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"e2eaeeff-423b-47e0-ae9e-fabb69967767","acronym":"NRG-GY033","url":"https://clinicaltrials.gov/study/NCT06169124","created_at":"2023-12-13T21:16:59.860Z","updated_at":"2024-07-02T16:34:27.588Z","phase":"Phase 2","brief_title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","source_id_and_acronym":"NCT06169124 - NRG-GY033","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 02/08/2024","start_date":" 02/08/2024","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-06-10"},{"id":"1bd14822-da3c-4dbb-9782-85f6d5deab4b","acronym":"PREDICT-RT","url":"https://clinicaltrials.gov/study/NCT04513717","created_at":"2021-01-18T21:37:58.373Z","updated_at":"2024-07-02T16:35:20.440Z","phase":"Phase 3","brief_title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","source_id_and_acronym":"NCT04513717 - PREDICT-RT","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 2478","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/31/2033","primary_completion_date":" 12/31/2033","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2024-02-07"},{"id":"77650eab-43cf-4fc1-b1f7-8de4c87fdc86","acronym":"TEXT","url":"https://clinicaltrials.gov/study/NCT00066703","created_at":"2021-01-18T00:09:39.799Z","updated_at":"2024-07-02T16:35:24.835Z","phase":"Phase 3","brief_title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","source_id_and_acronym":"NCT00066703 - TEXT","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" PGR","pipe":" | ","alterations":" HR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2672","initiation":"Initiation: 11/03/2003","start_date":" 11/03/2003","primary_txt":" Primary completion: 03/11/2011","primary_completion_date":" 03/11/2011","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-01"},{"id":"640609e9-2da6-4db9-b6e8-6e6536e01f20","acronym":"","url":"https://clinicaltrials.gov/study/NCT06050109","created_at":"2023-09-22T14:10:44.161Z","updated_at":"2024-07-02T16:35:33.871Z","phase":"","brief_title":"The Benefits of Continued Use of Ovarian Function Suppression After 5 Years","source_id_and_acronym":"NCT06050109","lead_sponsor":"Hongmei Zheng","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2023-10-11"},{"id":"0f494b10-c7de-444c-8668-530d6e3b1c05","acronym":"Trace-II","url":"https://clinicaltrials.gov/study/NCT05555017","created_at":"2022-09-26T14:56:17.853Z","updated_at":"2024-07-02T16:35:34.518Z","phase":"Phase 2","brief_title":"Tracer-Guided Surgery for Recurrent Prostate Cancer","source_id_and_acronym":"NCT05555017 - Trace-II","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-10-06"},{"id":"c88bd8d2-1222-406c-ba31-c677f4047764","acronym":"ASCLEPIuS","url":"https://clinicaltrials.gov/study/NCT04194554","created_at":"2021-07-05T17:26:59.721Z","updated_at":"2024-07-02T16:35:37.018Z","phase":"Phase 1/2","brief_title":"A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer","source_id_and_acronym":"NCT04194554 - ASCLEPIuS","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" DRD","pipe":" | ","alterations":" DDR • DRD","tags":["DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-09-14"},{"id":"7f533462-a837-49b6-9a00-e49641b1aa12","acronym":"","url":"https://clinicaltrials.gov/study/NCT06009627","created_at":"2023-08-24T16:11:33.037Z","updated_at":"2024-07-02T16:35:39.072Z","phase":"Phase 2/3","brief_title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","source_id_and_acronym":"NCT06009627","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 expression • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • epirubicin • exemestane • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 04/11/2023","start_date":" 04/11/2023","primary_txt":" Primary completion: 03/11/2025","primary_completion_date":" 03/11/2025","study_txt":" Completion: 09/11/2026","study_completion_date":" 09/11/2026","last_update_posted":"2023-08-24"},{"id":"4415345d-a697-4291-8d70-7d0798eb8ec4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05945407","created_at":"2023-07-14T18:08:53.504Z","updated_at":"2024-07-02T16:35:42.902Z","phase":"","brief_title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","source_id_and_acronym":"NCT05945407","lead_sponsor":"Peking University People's Hospital","biomarkers":" TP53 • PTEN • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • PTEN • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-07-14"},{"id":"8a3b861b-e6d7-4999-9657-66fbacd7d7d6","acronym":"TEXT-Bone","url":"https://clinicaltrials.gov/study/NCT00963417","created_at":"2021-01-18T03:45:06.718Z","updated_at":"2024-07-02T16:35:46.911Z","phase":"","brief_title":"Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02","source_id_and_acronym":"NCT00963417 - TEXT-Bone","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" IGF1 • IGFBP3","pipe":" | ","alterations":" HR positive","tags":["IGF1 • IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 08/03/2009","start_date":" 08/03/2009","primary_txt":" Primary completion: 03/11/2011","primary_completion_date":" 03/11/2011","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-05-31"},{"id":"e41c144f-2da7-46cf-9299-86352e820bdd","acronym":"INTERSTELLAR","url":"https://clinicaltrials.gov/study/NCT05333328","created_at":"2022-04-18T15:53:02.383Z","updated_at":"2024-07-02T16:35:55.935Z","phase":"Phase 4","brief_title":"OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk","source_id_and_acronym":"NCT05333328 - INTERSTELLAR","lead_sponsor":"Gangnam Severance Hospital","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 418","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2033","study_completion_date":" 01/01/2033","last_update_posted":"2023-02-09"},{"id":"f84cabea-5f2b-4fb9-94d9-3abd26fbd973","acronym":"SEAT","url":"https://clinicaltrials.gov/study/NCT02440230","created_at":"2021-01-18T11:41:24.661Z","updated_at":"2024-07-02T16:35:58.371Z","phase":"Phase 2","brief_title":"Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients","source_id_and_acronym":"NCT02440230 - SEAT","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • exemestane • goserelin acetate"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2022-12-30"},{"id":"b7feea87-0a0a-414b-a492-5991c4b642bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535221","created_at":"2021-01-18T12:15:34.357Z","updated_at":"2024-07-02T16:36:20.140Z","phase":"Phase 3","brief_title":"Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ \u0026 HER2- Breast Cancer","source_id_and_acronym":"NCT02535221","lead_sponsor":"Peking University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epirubicin • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 07/29/2015","start_date":" 07/29/2015","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2021-11-29"},{"id":"459e59f3-4bd2-45dd-9278-4861f3a5c060","acronym":"","url":"https://clinicaltrials.gov/study/NCT05122377","created_at":"2021-11-16T12:53:42.649Z","updated_at":"2024-07-02T16:36:20.650Z","phase":"","brief_title":"RWE About QOL and Compliance of Patients With OFS in China","source_id_and_acronym":"NCT05122377","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2021-11-16"},{"id":"0b63362f-4ed6-4b42-aae6-d28bb107156e","acronym":"SOFT-EST","url":"https://clinicaltrials.gov/study/NCT00975676","created_at":"2021-01-18T03:48:15.006Z","updated_at":"2024-07-02T16:36:22.522Z","phase":"","brief_title":"Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02","source_id_and_acronym":"NCT00975676 - SOFT-EST","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • triptorelin • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 11/25/2008","start_date":" 11/25/2008","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2021-10-25"},{"id":"6f798f51-0868-461a-afee-66766b7e79e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04891731","created_at":"2021-09-07T19:53:27.510Z","updated_at":"2024-07-02T16:36:30.117Z","phase":"","brief_title":"Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer","source_id_and_acronym":"NCT04891731","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" ER","pipe":" | ","alterations":" PGR expression","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-05-18"},{"id":"faac3d4c-5fd1-4b85-84ff-d3d64f72af79","acronym":"LARES","url":"https://clinicaltrials.gov/study/NCT03658213","created_at":"2021-01-18T17:57:11.214Z","updated_at":"2024-07-02T16:36:30.522Z","phase":"Phase 3","brief_title":"To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.","source_id_and_acronym":"NCT03658213 - LARES","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e goserelin acetate"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/31/2020","start_date":" 03/31/2020","primary_txt":" Primary completion: 11/04/2021","primary_completion_date":" 11/04/2021","study_txt":" Completion: 11/04/2021","study_completion_date":" 11/04/2021","last_update_posted":"2021-05-10"},{"id":"3588961f-d71c-4ccb-84ad-0fe266727d7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01338987","created_at":"2021-01-18T05:27:36.184Z","updated_at":"2024-07-02T16:36:33.134Z","phase":"Phase 2","brief_title":"Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation","source_id_and_acronym":"NCT01338987","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • ABL1 • BCR • KMT2A • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • ABL1 • BCR • KMT2A • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • methotrexate • fludarabine IV • busulfan • leuprolide acetate for depot suspension • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 04/19/2011","start_date":" 04/19/2011","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 11/19/2020","study_completion_date":" 11/19/2020","last_update_posted":"2021-03-18"},{"id":"fe7a7604-ae85-4796-8014-d187449bf1e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00970203","created_at":"2021-01-29T06:59:56.961Z","updated_at":"2024-07-02T16:36:39.189Z","phase":"Phase 2","brief_title":"Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer","source_id_and_acronym":"NCT00970203","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e goserelin acetate"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 10/05/2018","primary_completion_date":" 10/05/2018","study_txt":" Completion: 10/05/2019","study_completion_date":" 10/05/2019","last_update_posted":"2020-11-03"}]